ANI Pharmaceuticals (ANI Pharmaceuticals) Days Sales Outstanding : 118.15 (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Days Sales Outstanding?

ANI Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $170.5 Mil. ANI Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $131.7 Mil. Hence, ANI Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 118.15.

The historical rank and industry rank for ANI Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

ANIP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 93.8 Med: 116.48 Max: 189.41
Current: 128.06

During the past 13 years, ANI Pharmaceuticals's highest Days Sales Outstanding was 189.41. The lowest was 93.80. And the median was 116.48.

ANIP's Days Sales Outstanding is ranked worse than
85.39% of 999 companies
in the Drug Manufacturers industry
Industry Median: 72.15 vs ANIP: 128.06

ANI Pharmaceuticals's Days Sales Outstanding declined from Dec. 2022 (148.10) to Dec. 2023 (118.15).

ANI Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for ANI Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Days Sales Outstanding Chart

ANI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

121.02

147.00

189.41

169.57

122.78

ANI Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															148.10	145.33	136.09	121.74	118.15

Competitive Comparison of ANI Pharmaceuticals's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANI Pharmaceuticals's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Days Sales Outstanding falls into.

ANI Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

ANI Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (165.438	+	162.079)	/	2 )	/	486.816	*	365
=	163.7585					/	486.816	*	365
=	122.78

ANI Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (178.842	+	162.079)	/	2 )	/	131.654	*	365 / 4
=	170.4605					/	131.654	*	365 / 4
=	118.15

ANI Pharmaceuticals (NAS:ANIP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

ANI Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

BSFA:Germany

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Executives

Muthusamy Shanmugam	director, officer: HEAD OF R&D, COO-NOVITIUM OPS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook	officer: SR. VP, GENERAL COUNSEL & SEC.	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis	officer: SVP, CHIEF HR OFFICER	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz	officer: HEAD OF RARE DISEASE	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert	officer: SVP - CORP. DEV. & STRATEGY	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg	officer: SVP, GENERICS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken	officer: Vice President, Operations	210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard	director	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp	10 percent owner
Nikhil Lalwani	director, officer: PRESIDENT & CEO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey	officer: Vice President and CFO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780